SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

From key drug updates to ASH 2021, the MPN Hub continues to enhance global knowledge of myeloproliferative neoplasms

12/15/2021 | 09:37am EDT

The MPN Hub, run by Scientific Education Support (SES) in partnership with the European LeukemiaNet (ELN), is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in myeloproliferative neoplasms (MPN). In the final quarter of 2021 (Q4), the MPN Hub has communicated significant developments in the research and treatment of MPN, including four major treatment approvals.

In Q4, the MPN Hub was delighted to cover the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition and looks forward to delivering materials on key takeaways in the MPN setting. In collaboration with our Steering Committee, the MPN Hub provided a downloadable resource recommending the top abstracts to look for in MPN at ASH 2021. Additionally, we virtually attended the 2021 International Congress on Myeloproliferative Neoplasms, providing live coverage of key sessions and joining the conversation on Twitter.

The MPN Hub aims to address uncertainties caused by the ever-changing COVID-19 situation, and remains dedicated to supporting healthcare professionals throughout the pandemic, delivering information on its impact on the MPN community.

The MPN Hub would like to thank Bristol Myers Squibb, AbbVie, CTI BioPharma, Novartis, Kartos Therapeutics, AOP Orphan, Constellation Pharmaceuticals, Geron, and Sierra Oncology for their continued support of the platform.

Reviewing the MPN Hub's impact this quarter, Mia Hill, IME Director at Scientific Education Support, said:

"We were delighted to round off 2021 with extensive coverage of the 63rd ASH Annual Meeting and Exposition, navigating the hybrid format and capturing key information around developments in MPN. The MPN Hub also proudly reported 8 major drug updates including four treatment approvals. Namely, mepolizumab

was approved by the U.S. Food and Drug administration (FDA) and European Commission for the treatment of hypereosinophilic syndrome, and ropeginterferon alfa-2b-njft

received approval from both the FDA and Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of polycythemia vera. We look forward to delivering more crucial updates to the MPN community and a prosperous 2022."


For more information on the MPN Hub, please visit

For media enquiries or to explore opportunities for collaboration, please contact


About myeloproliferative neoplasms (MPN)

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers where the body produces too many red blood cells, white blood cells, or platelets. The three main types include myelofibrosis, polycythemia vera, and essential thrombocythemia.

About the MPN Hub

The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge of MPN through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world. Informed by patients, curated by world leaders, and endorsed by expert societies, the MPN Hub supports HCPs worldwide.

Founded in partnership with the European LeukemiaNet (ELN) in 2020, the MPN Hub is guided by an international steering committee of experts in the field of MPN. The steering committee meet regularly to discuss the performance of the MPN Hub and to devise action plans on how best to support the MPN community and address any unmet educational needs.

MPN supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

Bristol Myers Squibb


CTI BioPharma


Kartos Therapeutics

AOP Orphan

Constellation Pharmaceuticals


Sierra Oncology

If you are interested in becoming an MPN Hub supporter, please contact

About Scientific Education Support (SES)

SES is a medical education company providing projects such as community physician education through our therapy hubs, community awareness and education through our 'Know' education initiatives, and academic researcher education through the Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hematological-oncology: the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and Multiple Myeloma Hub.

About The European LeukemiaNet

220 participating centers in 44 countries with more than 1000 researchers and clinicians are cooperating in the European LeukemiaNet. The objective is to integrate the about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a network promoting cooperative research for curing leukemia.

Distributed by


(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.70% 78.22 Delayed Quote.25.45%
CTI BIOPHARMA CORP. -2.22% 4.4 Delayed Quote.77.42%
SIERRA ONCOLOGY, INC. 0.11% 54.64 Delayed Quote.151.06%
04:12pBerkshire Hathaway Divests Wells Fargo Stake, Picks Up Citi Shares in Portfolio Reshuff..
11:20aWells Fargo Adjusts Bristol-Myers Squibb's Price Target to $70 from $65, Keeps Equalwei..
05/16Berkshire Hathaway Exited Bristol Myers and AbbVie Stakes in 1Q
05/16Bristol Myers Squibb Says Phase 3 Trial of Urothelial Cancer Combination Therapy Didn't..
05/16Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolum..
05/16Bristol Myers Squibb Provides Update on Checkmate -901 Trial Evaluating Opdivo Plus Yer..
05/16Bristol Myers Squibb Trial of Carcinoma Treatments Fails to Meet Primary Endpoint
05/13Berenberg Bank Adjusts Price Target on Bristol-Myers Squibb to $82 From $80, Maintains ..
05/13Bristol-Myers Squibb Selling East Syracuse, New York Manufacturing Facility To LOTTE
05/13LOTTE to Purchase Bristol Myers Squibb Manufacturing Facility in East Syracuse, New Yor..
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2022 46 561 M - -
Net income 2022 7 451 M - -
Net Debt 2022 21 743 M - -
P/E ratio 2022 27,1x
Yield 2022 2,75%
Capitalization 167 B 167 B -
EV / Sales 2022 4,04x
EV / Sales 2023 3,67x
Nbr of Employees 32 200
Free-Float 72,8%
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 78,22 $
Average target price 77,98 $
Spread / Average Target -0,31%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Samit Hirawat Chief Medical Officer-Global Drug Development
Rupert J. Vessey Executive VP-Research & Early Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.53%468 600
PFIZER, INC.-13.06%284 304
ABBVIE INC.14.31%274 733
ROCHE HOLDING AG-14.96%260 807